Eli Lilly and Company (NYSE:LLY) Trading 1.8% Higher – What’s Next?

Eli Lilly and Company (NYSE:LLY)’s share price traded up 1.8% on Monday . The company traded as high as $995.00 and last traded at $965.8490. 3,102,072 shares traded hands during trading, a decline of 3% from the average session volume of 3,212,879 shares. The stock had previously closed at $948.45.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s new phase 3 obesity data suggest Foundayo and lower-dose Zepbound can preserve weight-loss results, strengthening confidence in its obesity franchise and future growth. Lilly’s Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
• Positive Sentiment: Coverage highlighting Lilly’s strategy to expand beyond tirzepatide with next-generation obesity drugs, including an oral pill and retatrutide, may reassure investors that the company is protecting its leadership position. Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead
• Positive Sentiment: Additional long-term data for Omvoh in ulcerative colitis adds another proof point for Lilly’s non-obesity pipeline and supports the broader growth story. Eli Lilly’s Omvoh Data Extends Ulcerative Colitis Story And Valuation Appeal
• Neutral Sentiment: Lilly is celebrating its 150th anniversary with various company, community, and leadership-profile stories, but these are mostly reputational and unlikely to move the stock much on their own. Lilly CEO David Ricks keeps eye on future while company celebrates history
• Neutral Sentiment: Reuters reported Lilly launched its Alzheimer’s drug in India, a positive commercial development, but the immediate financial impact may be limited given the market’s focus on obesity growth. Eli Lilly launches Alzheimer’s drug Donanemab in India
• Negative Sentiment: Rival GLP-1 developers and new obesity entrants, including Kailera Therapeutics, add competitive pressure and show that Lilly’s market will remain highly contested. This Weight-Loss Drug Challenger Could Follow Eli Lilly’s Playbook: Analyst
• Negative Sentiment: Reports that Lilly paused an obesity awareness campaign in India after regulatory notices could be a modest headwind, though it does not appear to be a major earnings issue. Eli Lilly pauses Indian obesity awareness campaign after regulatory notices: report

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Freedom Capital upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 10th. Truist Financial reiterated a “buy” rating on shares of Eli Lilly and Company in a report on Monday, February 23rd. TD Cowen increased their price target on Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. The Goldman Sachs Group increased their price target on Eli Lilly and Company from $1,260.00 to $1,283.00 and gave the stock a “buy” rating in a report on Friday, May 1st. Finally, Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Tuesday, March 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,218.33.

Eli Lilly and Company Price Performance

The firm has a market cap of $955.80 billion, a price-to-earnings ratio of 36.05, a P/E/G ratio of 1.08 and a beta of 0.48. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The business has a 50 day simple moving average of $939.87 and a 200-day simple moving average of $995.67.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company’s quarterly revenue was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts expect that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company’s payout ratio is 24.58%.

Hedge Funds Weigh In On Eli Lilly and Company

Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of Eli Lilly and Company by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock worth $88,087,193,000 after buying an additional 1,006,885 shares in the last quarter. State Street Corp raised its stake in shares of Eli Lilly and Company by 1.8% during the 4th quarter. State Street Corp now owns 35,361,916 shares of the company’s stock worth $38,002,744,000 after purchasing an additional 635,358 shares during the period. Capital Research Global Investors boosted its holdings in shares of Eli Lilly and Company by 20.9% in the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after buying an additional 4,332,008 shares during the last quarter. Morgan Stanley boosted its holdings in shares of Eli Lilly and Company by 2.7% in the 4th quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock worth $16,757,510,000 after buying an additional 407,166 shares during the last quarter. Finally, Capital World Investors boosted its holdings in shares of Eli Lilly and Company by 0.4% in the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock worth $16,154,619,000 after buying an additional 61,851 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.